Reviewing Whitehawk Therapeutics (WHWK) and Its Peers

Whitehawk Therapeutics (NASDAQ:WHWK) is one of 451 public companies in the “Pharmaceutical Preparations” industry, but how does it compare to its rivals? We will compare Whitehawk Therapeutics to related companies based on the strength of its profitability, risk, dividends, earnings, valuation, analyst recommendations and institutional ownership.

Volatility & Risk

Whitehawk Therapeutics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Whitehawk Therapeutics’ rivals have a beta of 10.24, suggesting that their average stock price is 924% more volatile than the S&P 500.

Earnings and Valuation

This table compares Whitehawk Therapeutics and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Whitehawk Therapeutics	$25.98 million	-$63.69 million	15.57
Whitehawk Therapeutics Competitors	$440.95 million	-$69.10 million	-9.46

Whitehawk Therapeutics’ rivals have higher revenue, but lower earnings than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Whitehawk Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	99.42%	-68.32%	-63.21%
Whitehawk Therapeutics Competitors	-2,625.49%	-359.57%	-43.35%

Institutional and Insider Ownership

52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 39.5% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Whitehawk Therapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1	1	0	0	1.50
Whitehawk Therapeutics Competitors	4798	9964	16003	371	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 119.85%. Given Whitehawk Therapeutics’ rivals stronger consensus rating and higher possible upside, analysts plainly believe Whitehawk Therapeutics has less favorable growth aspects than its rivals.

Summary

Whitehawk Therapeutics rivals beat Whitehawk Therapeutics on 7 of the 13 factors compared.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.